Ryan Cross interviewed our CEO, Dan Mandell, PhD, about how the Company’s GRO platform expands the limited amino acid alphabet that nature uses to make proteins, and how our Series B financing will enable the first human trial of our lead program in refractory gout.
From the article: “Its first target: improving treatments for gout. Some people with gout receive infusions of a therapeutic enzyme called uricase that breaks down the painful crystals made of uric acid built up from excess protein. But the drug stops working for some patients when their immune system develops antibodies that attack the foreign enzyme. GRObio believes it has built a better uricase whose effectiveness won’t wane over time, and incorporated non-standard amino acids into the enzyme to control exactly how the protein is decorated with sugar molecules called glycans.”
